UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 0-19961 ORTHOFIX MEDICAL INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) ...

Exhibit 99.1 Orthofix Reports Fourth Quarter and Full Year 2023 Results Recent Highlights LEWISVILLE, Texas — March 5, 2024 — Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial results for the fourth quarter and year ended December 31, 2023, and issued guidance for the full year 2024. Fourth quarter net sales were $200.4 million, an increase of 64% on a reported basis and 7% on a pro forma constant currency basis. Net loss was $(22.2) million and earnings per share ("EPS") was $(0.59) on a rep ...

Financial Data and Key Metrics Changes - Revenue for Q3 2023 was $184 million, representing a growth of 61% on a reported basis and 1.2% on a pro forma basis, with pro forma revenue growth of 8.4% after normalizing for a one-time stocking order in Q3 2022 [5][24] - Adjusted EBITDA for Q3 2023 was $13.5 million, a 36% improvement sequentially over Q2 2023 [5][30] - GAAP gross margins for Q3 2023 were 65%, down from 73% in Q3 2022, while adjusted gross margin was 71%, compared to 74% in the prior year [25][26] Business Line Data and Key Metrics Changes - Bone Growth Therapy (BGT) revenue reached a record $53.4 million, marking a 15% year-over-year increase and the third consecutive period of double-digit growth [10][24] - Spinal Implants, Biologics, and Enabling Technologies reported global revenue of $101 million, a decrease of 6% on a pro forma basis, but a normalized growth of 5.8% year-over-year when accounting for a large stocking order in the prior year [13] - Global Orthopedics segment revenue totaled $29.7 million, reflecting approximately 7% year-over-year growth, with a 14% increase in the US [19][25] Market Data and Key Metrics Changes - The US Orthopedics market showed strong growth momentum, driven by investments in sales and marketing, with a reported 14% growth [19] - Internationally, there was a 3% contraction on a constant currency basis, attributed to significant international stocking orders in Q3 2022 [20] Company Strategy and Development Direction - The company is focused on driving profitable growth and maintaining strong relationships with distributor and surgeon partners, with a robust pipeline of new distributors and products [22][23] - The integration of Orthofix and SeaSpine is progressing without significant disruption, and the company anticipates announcing a permanent CEO by the end of the year [9][21] Management's Comments on Operating Environment and Future Outlook - Management noted a complicated competitive environment with market turbulence affecting decision-making, but expressed confidence in the stability of the sales force and distributor relationships [43][50] - The company updated its 2023 revenue guidance to a range of $739 million to $744 million, reflecting a 5.4% to 6.2% pro forma growth over the prior year [22][35] Other Important Information - Cash and cash equivalents as of September 30, 2023, totaled $34 million, with $70 million of outstanding borrowings under a $175 million credit facility [32] - Free cash flow for Q3 2023 was an outflow of $21.9 million, attributed to investments in inventory and capital instruments [34] Q&A Session Summary Question: Can you walk us through the implied Q4 guide and what is driving it? - Management indicated that the guidance reflects a combination of sales dislocation and prudence due to market uncertainty, with a strong distributor pipeline [42][48] Question: What is the risk from larger distributors and the selling footprint? - Management expressed confidence in the stability of distributor relationships and ongoing onboarding of new distributors, despite a near-term slowdown in decision-making [50][51]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 0-19961 ORTHOFIX MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 98-1340767 (State or other jurisd ...

Orthofix Medical Inc. (NASDAQ:OFIX) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET Company Participants Louisa Smith - Vice President of Investor Relations, Gilmartin Group LLC Keith Valentine - Chief Executive Officer John Bostjancic - Chief Financial Officer Conference Call Participants Mathew Blackman - Stifel Financial Corp. Jeffrey Cohen - Ladenburg Thalmann & Co. Inc. David Turkaly - JMP Group LLC Operator Ladies and gentlemen, good afternoon. My name is Abby, and I will be your conference ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 0-19961 ORTHOFIX MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 98-1340767 (State or other jurisdictio ...

Orthofix Medical Inc. (NASDAQ:OFIX) Q1 2023 Results Conference Call May 9, 2023 4:30 PM ET Company Participants Alexa Huerta - Senior Director, Investor Relations Keith Valentine - President and Chief Executive Officer John Bostjancic - Chief Financial Officer Conference Call Participants Mathew Blackman - Stifel Operator Thank you for standing by. My name is Brendan, and I'll be your conference operator today. At this time, I would like to welcome everyone to the Orthofix Medical Inc. Quarter One Earnings ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 0-19961 ORTHOFIX MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 98-1340767 (State or other jurisdicti ...

Orthofix Medical Inc. (NASDAQ:OFIX) Q4 2022 Earnings Conference Call March 6, 2023 4:30 PM ET Company Participants Alexa Huerta - Senior Director, Investor Relations Keith Valentine - President and Chief Executive Officer John Bostjancic - Chief Financial Officer Jon Serbousek - Director, Executive Chairman of the Board Doug Rice - Former Chief Financial Officer Conference Call Participants Mathew Blackman - Stifel Jeffrey Cohen - Ladenburg Thalmann Dave Turkaly - JMP Securities Operator Good afternoon and ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Address of principal executive offices) (Zip Code) (214) 937-2000 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: For the transition period f ...